Found 17 matching trials
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma PHASE2 RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and de...
Show More Location
University of Alabama at Birmingham Comprehensive Cancer Center
Learn More & Join Trial
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma PHASE2 RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritum...
Show More Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma EARLY_PHASE1 This phase I trial is studying how well monoclonal antibody therapy with pe...
Show More Location
Johns Hopkins University
Learn More & Join Trial
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma PHASE1 Phase I/II trial to study the effectiveness of combining radiolabeled monoc...
Show More Learn More & Join Trial
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan N/A This study is a regulatory post-marketing surveillance of Zevalin (ibritumo...
Show More Location
Multiple Locations
Learn More & Join Trial
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL PHASE1 Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxet...
Show More Location
Northwestern University
Learn More & Join Trial
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder PHASE1 Phase I/II trial to study the effectiveness of combining yttrium Y 90 ibrit...
Show More Location
AIDS - Associated Malignancies Clinical Trials Consortium
Learn More & Join Trial
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma PHASE2 This phase II trial studies the side effects and how well high-dose yttrium...
Show More Location
Fred Hutch/University of Washington Cancer Consortium
Learn More & Join Trial
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma N/A RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositum...
Show More Location
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Learn More & Join Trial
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan PHASE2 RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chem...
Show More Location
City of Hope Medical Center
Learn More & Join Trial